Nucleotide Metabolic Flux Analysis Service - Creative Proteomics Metabolomics

Q: How does Nucleotide MFA distinguish de novo synthesis from salvage pathways?

By administering specific ring precursors such as [1,2‑ 13 C 2 ]glycine or [U‑ 13 C 4 , 15 N]aspartate, newly assembled purine and pyrimidine rings incorporate the labeled atoms, generating characteristic mass shifts (e.g. M+2 in purines from glycine; M+3/M+4 in pyrimidines from aspartate). In contrast, salvage pathways utilize preformed nucleobases or nucleosides. Evaluating tracer incorporation alongside precursor enrichment allows mathematical deconvolution of de novo versus salvage pathway contributions.

Q: How is thymidylate synthase (TYMS) flux measured?

Using [3‑ 13 C]serine, SHMT transfers the β-carbon into 5,10‑methylene‑THF. Thymidylate synthase (TYMS) transfers this labeled one‑carbon unit onto dUMP to produce dTMP, resulting in a characteristic M+1 mass shift in dTMP/dTTP. Measuring M+1 dTMP formation over time provides a robust metric of TYMS‑mediated one‑carbon flux.

Q: Can Nucleotide MFA quantify Ribonucleotide Reductase (RNR) activity?

Yes. By tracing [U‑ 13 C 6 ]glucose into the ribose ring (M+5) of ribonucleotides (NDPs) and following the transfer of this M+5 label into deoxyribonucleotides (dNDPs and dNTPs), stoichiometric network modeling estimates the reduction throughput of RNR when constrained by cell proliferation rates.

Q: What statistical metrics validate the calculated nucleotide fluxes?

Calculated fluxes are validated using global Chi‑square goodness‑of‑fit testing against measurement variance. Furthermore, parameter sensitivity analysis and confidence intervals are computed for all estimated fluxes to verify that reported parameters are mathematically identifiable and robustly constrained by the experimental dataset.

Nucleotide Metabolic Flux Analysis — Beyond Static Pool Concentrations

Nucleotides serve as the fundamental building blocks for nucleic acid synthesis, energy currency (ATP/GTP), and coenzyme precursors (NAD⁺/FAD/CoA). While conventional metabolomics measures static intracellular pool concentrations (μmol/g or μM), pool sizes alone cannot determine whether nucleotide depletion or accumulation is driven by altered de novo synthesis, salvage pathway activation, impaired degradation, or antimetabolite drug inhibition.

As a specialized pathway Spoke within our central carbon metabolic flux analysis and broader metabolic flux analysis service, Nucleotide MFA tracks stable isotopes (¹³C and ¹⁵N) to resolve key reaction velocities across five critical nucleotide decision nodes:

(i) De Novo Purine Synthesis Velocity: Stepwise ring assembly from PRPP to inosine monophosphate (IMP) and branching into AMP (ADSL) and GMP (IMPDH), tracking carbon inputs from glycine, one-carbon folates (10-CHO-THF), and CO₂ alongside nitrogen inputs from glutamine and aspartate.

(ii) De Novo Pyrimidine Assembly & dTMP Synthesis: CAD-catalyzed carbamoyl phosphate condensation with aspartate yielding orotate and UMP, and downstream thymidylate synthase (TYMS) flux utilizing 5,10-methylene-THF, connected to our one-carbon metabolic flux analysis.

(iii) De Novo vs. Salvage Pathway Partitioning: Quantifying the fractional reliance on hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and thymidine kinase (TK1) versus de novo assembly under genetic or therapeutic perturbations.

(iv) Ribonucleotide Reductase (RNR) Flux & dNTP Supply: Tracking the reduction throughput of ribonucleoside diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs), supporting replication precursor balancing.

(v) Pentose Phosphate Pathway & PRPP Coupling: Calculating phosphoribosyl pyrophosphate (PRPP) synthesis rate from ribose-5-phosphate, linked to our pentose phosphate pathway analysis resource.

Looking for nucleotide concentration measurements? If your research focuses on quantifying absolute or relative pool sizes (μmol/g, μmol/L, or ng/mL) of free nucleotides, nucleosides, or nucleobases without stable isotope tracing, please explore our Nucleotide Metabolism Service.

Analytical Considerations in High-Resolution Nucleotide Fluxomics

Nucleotide fluxomics requires specialized bioanalytical protocols to stabilize labile triphosphates and resolve highly polar isobaric isomers:

Rapid Low-Temperature Quenching & Acid Extraction: Intracellular NTPs, dNTPs, and PRPP have rapid turnover kinetics and are highly susceptible to enzymatic phosphatase hydrolysis. Rapid quenching in pre-chilled organic/acidic solvent mixtures halts phosphatase activity instantly.
Ion-Pair & HILIC LC-MS/MS Resolution: Specialized reversed-phase ion-pairing or high-resolution hydrophilic interaction liquid chromatography (HILIC) separates mono-, di-, and triphosphate nucleotides (e.g. AMP, ADP, ATP, dATP) without on-column degradation.
Multi-Isotope ¹³C and ¹⁵N Mass Isotopologue Acquisition: High-resolution mass spectrometry resolves fine isotopic structures (differentiating ¹³C from ¹⁵N mass shifts), enabling concurrent tracking of ribose rings, purine/pyrimidine nucleobases, and amino nitrogen donors.
Multi-Element Background Deconvolution: Algorithmic matrix deconvolution (IsoCor / AccuCor) mathematically corrects raw isotopologue spectra for natural ¹³C, ¹⁵N, ¹⁸O, and phosphate background.

13C and 15N Tracer Selection Matrix for Purine & Pyrimidine Networks

The choice of isotope tracer dictates which nucleotide synthetic, salvage, and interconversion pathways can be mathematically resolved:

Tracer Substrate	Target Nucleotide Pathway Node	Diagnostic Labeling Information & Readout
[1,2-¹³C₂]Glycine	De Novo Purine Ring Assembly (C4, C5, N7 backbone)	Glycine is incorporated intact into the purine ring at the GART step. De novo synthesized IMP, AMP, and GMP display characteristic M+2 mass shifts, providing robust diagnostic labeling to estimate de novo purine synthesis when evaluated alongside precursor enrichment and pool turnover.
[3-¹³C]Serine	One-Carbon Donation to Purine (C2, C8) & Thymidylate (dTMP)	SHMT cleavage transfers ¹³C into 10-CHO-THF (labeling C2 and C8 of purines, generating M+1 and M+2 purines) and into 5,10-CH₂-THF (generating M+1 dTMP via TYMS). Resolves one-carbon-driven nucleotide flux.
[U-¹³C₄, ¹⁵N]Aspartate	De Novo Pyrimidine Ring Assembly (C4, C5, C6, N1) & Purine C6-NH₂	Condensation with carbamoyl phosphate via CAD introduces a 3-carbon, 1-nitrogen unit into orotate, UMP, and CTP (M+3/M+4). In purine synthesis, aspartate donates its amino group to form adenylosuccinate, transferring ¹⁵N into AMP.
[¹⁵N-amide]Glutamine	Nitrogen Donation for Purine (N3, N9) & Pyrimidine (N3) Rings	Specifically traces nitrogen donation by glutamine amidotransferases (PPAT, PFAS in purines; CPS2 in pyrimidines; CTP synthetase). Yields M+1 and M+2 nitrogen shifts in newly synthesized nucleotide rings.
[U-¹³C₆]Glucose	PRPP Ribose Synthesis & Global Carbon Influx	Traces pentose phosphate pathway entry into ribose-5-phosphate (M+5), labeling the phosphoribosyl backbone (M+5) of all ribonucleotides and deoxyribonucleotides.

Technical Capabilities for High-Resolution Nucleotide Flux Analysis

Integrated Multi-Isotope Balance: Stoichiometric modeling accounting simultaneously for carbon atom routing from glycolysis/amino acids and nitrogen transfer from glutamine and aspartate.
De Novo vs. Salvage Pathway Deconvolution: Accurately estimates model-supported proportions of cellular nucleotides derived from de novo synthesis versus extracellular nucleobase salvage under verified tracer designs.
Isotopic Steady-State and Dynamic Kinetic Sampling: Supports steady-state fractional contribution studies as well as time-course dynamic and INST metabolic flux analysis to evaluate acute responses to antimetabolite drugs (e.g. 5-FU, methotrexate, hydroxyurea, 6-MP).
Complementary Positional Validation: High-field NMR-based metabolic flux analysis available for resolving position-specific carbon and nitrogen labeling in complex biological matrices.

End-to-End Nucleotide MFA Workflow & Analytical Pipeline

Study Scoping & Network Configuration

We define the nucleotide metabolic network (purine de novo, pyrimidine de novo, salvage pathways, RNR reductions) and select optimal ¹³C/¹⁵N tracer regimes matched to your research questions.

Tracer Incubation & Rapid Acid Quenching

Cultured cells or tissues are labeled with validated stable isotope tracers and harvested using pre-chilled organic/acidic solvent quenching to arrest phosphatase activity immediately.

High-Resolution LC-MS/MS Data Acquisition

Intact ribonucleotides (NTPs, NDPs, NMPs), deoxyribonucleotides (dNTPs), nucleosides, and nucleobases are acquired for mass isotopologue distributions (M+0 to M+n); extracellular rates are measured in parallel.

Natural Abundance Deconvolution & QC Review

Raw mass isotopologue profiles are algorithmically stripped of natural isotope background using IsoCor/AccuCor, verified with pooled quality control (QC) standards.

Mathematical Modeling & Uncertainty Estimation

Stoichiometric and isotopomer balance equations compute de novo synthesis rates, salvage fractions, and RNR velocities with parameter sensitivity and confidence interval evaluation.

Publication-Ready Flux Maps & Deliverables

Delivery of comprehensive quantitative datasets, model configuration files, and publication-oriented vector pathway maps supported by our fluxomics data analysis service.

Six-step workflow for nucleotide metabolic flux analysis

Sample Preparation & Stabilization Guidelines for Nucleotide MFA

Sample amounts and extraction protocols are finalized during feasibility review based on cellular proliferation rate and matrix type:

Sample Type	Typical Input Guidelines	Harvesting & Quenching Principles	Storage & Transport
Adherent Cultured Cells	Typically 2–10 × 10⁶ cells (100 mm dish or two 60 mm dishes)	Aspirate tracer medium rapidly, rinse with ice-cold PBS, add pre-chilled acidic extraction solvent (e.g. cold methanol/formic acid), scrape on dry ice/ice.	Store at −80 °C; ship on dry ice
Suspension Cultured Cells	Typically 5–15 × 10⁶ cells, adjusted to cell density	Short, pre-cooled centrifugation (4 °C), aspirate supernatant, extract cell pellet immediately in cold acidic extraction solvent.	Store at −80 °C; ship on dry ice
Animal & Tumor Tissues	20–50 mg wet weight, depending on metabolic activity	Instant freeze-clamping or flash freezing in liquid nitrogen immediately upon collection; cryo-pulverize without intermediate thawing.	Store at −80 °C; ship on dry ice
Blood Plasma / Serum	≥ 100 μL matched plasma or serum	Collect blood into EDTA tubes, centrifuge immediately (4 °C, 2,000 × g, 10 min), aliquot and freeze immediately for circulating nucleosides.	Store at −80 °C; ship on dry ice
Conditioned Culture Medium	≥ 200 μL matched supernatant	Sample matched culture supernatant across labeling time points; clarify by centrifugation (4 °C) to quantify nucleoside uptake and excretion.	Store at −80 °C; ship on dry ice

Deliverables & Quantitative Datasets from Nucleotide MFA

Deconvoluted Nucleotide MID Matrix: Natural-abundance-corrected fractional labeling (M+0 to M+n) across all ribonucleotides (AMP, ADP, ATP, GMP, GDP, GTP, UMP, UDP, UTP, CMP, CDP, CTP) and deoxyribonucleotides (dATP, dGTP, dCTP, dTTP).
De Novo vs. Salvage Pathway Quantification: Model-supported fractional contributions of cellular nucleotide pools derived from de novo synthesis versus salvage pathways under verified tracer designs.
Ribonucleotide Reductase (RNR) Flux Modeling: Calculated reduction kinetics generating dNDPs and dNTP pool balancing metrics under defined cellular growth constraints.
Stoichiometric Model Specifications: Complete reaction network definitions, carbon/nitrogen atom transition mappings, and project configuration files.
Statistical Fit Diagnostics: Sum of squared residuals (SSR), Chi-square goodness-of-fit evaluation, and residual diagnostic plots.
Publication-Ready Pathway Maps: High-resolution vector graphics (PDF/SVG) illustrating purine and pyrimidine flux partitioning.

Nucleotide mass isotopologue distribution bar plot resolving purine and pyrimidine labeling

Mass isotopologue distribution (MID) bar plot of ATP, GTP, UTP, and dTTP resolving de novo ring assembly (M+2 glycine, M+1/M+2 one-carbon) vs. unlabeled salvage pools.

Quantitative nucleotide metabolic pathway flux map with de novo and salvage rates

Publication-oriented nucleotide pathway flux map displaying de novo purine/pyrimidine synthesis, RNR reduction, and salvage pathway velocities with confidence intervals.

What Nucleotide Tracing Can Reliably Resolve: De Novo Synthesis, Salvage, Turnover, and dNTP Supply

Nucleotide stable-isotope tracing provides precise mechanistic insights into nucleic acid precursor supply, provided each biological conclusion is grounded in appropriate tracer selection and analytical constraints:

Biological Conclusion	Minimum Required Experimental Evidence	Analytical Scope & Interpretation Boundaries
De Novo Synthesis Velocity	Pathway-specific precursor tracer ([1,2-¹³C₂]glycine for purines, [U-¹³C₄, ¹⁵N]aspartate for pyrimidines), measured precursor pool enrichment, and nucleotide mass isotopologue distributions (MIDs).	Quantifies de novo ring assembly rate. True absolute de novo synthesis rates require accounting for actual intracellular precursor enrichment and pool size rather than assuming 100% tracer entry.
Salvage Pathway Contribution	Directly labeled nucleobase/nucleoside tracers (e.g. [¹³C]hypoxanthine, [¹³C]adenine, [¹³C]thymidine) or controlled exogenous base titration experiments.	Distinguishes salvage pathway reliance from de novo synthesis. An unlabeled (M+0) nucleotide pool cannot be automatically equated with salvage without verifying exogenous uptake and internal turnover dynamics.
Nucleotide Pool Turnover & Fractional Synthetic Rate (FSR)	Dynamic time-course labeling profiles ([U-¹³C₆]glucose into ribose or ¹³C-amino acids) paired with absolute pool-size quantification (μmol/gDW or μM).	Resolves the replacement kinetics and turnover velocity of intracellular NTP/dNTP pools. Single steady-state time points alone cannot distinguish rapid turnover from large stagnant intermediate pools.
Ribonucleotide Reductase (RNR) & dNTP Supply	Simultaneous MID tracking across matched ribonucleoside diphosphates (NDPs) and deoxyribonucleoside triphosphates (dNTPs) with growth rate and cell-cycle constraints.	Tracks the flow of ribose carbon through RNR into replication precursor pools. Observing M+5 labeling from NTP in dNTP confirms active RNR routing, but claiming absolute reduction velocities requires integrated kinetic flux modeling.

How does Nucleotide MFA distinguish de novo synthesis from salvage pathways?

By administering specific ring precursors such as [1,2-¹³C₂]glycine or [U-¹³C₄, ¹⁵N]aspartate, newly assembled purine and pyrimidine rings incorporate the labeled atoms, generating characteristic mass shifts (e.g. M+2 in purines from glycine; M+3/M+4 in pyrimidines from aspartate). In contrast, salvage pathways utilize preformed nucleobases or nucleosides. Evaluating tracer incorporation alongside precursor enrichment allows mathematical deconvolution of de novo versus salvage pathway contributions.

How is thymidylate synthase (TYMS) flux measured?

Using [3-¹³C]serine, SHMT transfers the β-carbon into 5,10-methylene-THF. Thymidylate synthase (TYMS) transfers this labeled one-carbon unit onto dUMP to produce dTMP, resulting in a characteristic M+1 mass shift in dTMP/dTTP. Measuring M+1 dTMP formation over time provides a robust metric of TYMS-mediated one-carbon flux.

Why is rapid acid quenching critical for nucleotide intermediate profiling?

Intracellular nucleoside triphosphates (ATP, GTP, UTP, CTP, dNTPs) are rapidly hydrolyzed into diphosphates and monophosphates by active nucleotidases and phosphatases within seconds of cell harvesting. Fast low-temperature quenching in acidic organic extraction solvents instantly denatures hydrolytic enzymes, preserving physiological phosphorylation states and accurate mass isotopologue distributions.

Can Nucleotide MFA quantify Ribonucleotide Reductase (RNR) activity?

Yes. By tracing [U-¹³C₆]glucose into the ribose ring (M+5) of ribonucleotides (NDPs) and following the transfer of this M+5 label into deoxyribonucleotides (dNDPs and dNTPs), stoichiometric network modeling estimates the reduction throughput of RNR when constrained by cell proliferation rates.

What statistical metrics validate the calculated nucleotide fluxes?

Calculated fluxes are validated using global Chi-square goodness-of-fit testing against measurement variance. Furthermore, parameter sensitivity analysis and confidence intervals are computed for all estimated fluxes to verify that reported parameters are mathematically identifiable and robustly constrained by the experimental dataset.